New Product:  NovoPen Junior

Bold New Look in Insulin Delivery and Flexible Dosing NovoPen(R) Junior Wins FDA Approval

NovoPen^® Junior, with half-unit dose increments to fine-tune small doses for children.

PRINCETON, N.J., April 15 /PRNewswire-FirstCall/ -- Novo Nordisk Pharmaceuticals, Inc., today announced the Food and Drug Administration has approved NovoPen® Junior, the first insulin delivery system enhanced with a colorful look for children and teenagers. Feauturing half-unit increments, NovoPen Junior is designed for children and adults alike who need the flexibility to finely tune their insulin doses. NovoPen Junior is a line extension of the company's NovoPen, the most widely used insulin pen in the world.

 

Designed in appealing, cheerful colors with children and teenagers in mind, NovoPen Junior provides an accurate, discreet, and convenient way to administer 1 to 35 units of insulin in half-unit increments. The all-in-one system is designed for use with Novo Nordisk's comprehensive range of PenFill® 3 mL cartridges, which contain 300 units of insulin. NovoPen Junior is used with NovoFine® disposable needles.

View The "New Product" Archives